Evidence map›Paper›PMID 36284309›Full record

ArticleClinical epigenetics2022

HPV infection and 5mC/5hmC epigenetic markers in penile squamous cell carcinoma: new insights into prognostics.

Renan da Silva Santos, Carlos Gustavo Hirth, Daniel Pascoalino Pinheiro, Maria Júlia Barbosa Bezerra, Isabelle Joyce de Lima Silva-Fernandes, Dayrine Silveira de Paula, Ana Paula Negreiros Nunes Alves, Manoel Odorico de Moraes Filho, Arlindo de Alencar Araripe Moura, Marcos Venício Alves Lima and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in Penile Cancer in Thailand.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Renan da Silva SantosDrug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.
Carlos Gustavo HirthLaboratory of Pathology, Cancer Institute of Ceará, Fortaleza, Brazil.
Daniel Pascoalino PinheiroDrug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.
Maria Júlia Barbosa BezerraLaboratory of Molecular Biology and Genetics, Cancer Institute of Ceará, Fortaleza, Brazil.
Isabelle Joyce de Lima Silva-FernandesLaboratory of Molecular Biology and Genetics, Cancer Institute of Ceará, Fortaleza, Brazil.
Dayrine Silveira de PaulaDepartment of Dental Clinic, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Fortaleza, Brazil.
Ana Paula Negreiros Nunes AlvesDrug Research and Development Center, Postgraduate Program in Translational Medicine, Federal University of Ceará, Fortaleza, Brazil.
Manoel Odorico de Moraes FilhoDrug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.
Arlindo de Alencar Araripe MouraDepartment of Animal Science, Federal University of Ceará, Fortaleza, Brazil.
Marcos Venício Alves LimaLaboratory of Pathology, Cancer Institute of Ceará, Fortaleza, Brazil.
Claudia do Ó Pessoa *Drug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.
Cristiana Libardi Miranda Furtado *Drug Research and Development Center, Postgraduate Program in Translational Medicine, Federal University of Ceará, Fortaleza, Brazil. clibardim@gmail.com.
Universidade Federal do Ceará · BRHospital Haroldo Juaçaba · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPenile cancer is one of the most aggressive male tumors. Although it is preventable, the main etiologic causes are lifestyle behaviors and viral infection, such as human papillomavirus (HPV). Long-term epigenetic changes due to environmental factors change cell fate and promote carcinogenesis, being an important marker of prognosis. We evaluated epidemiological aspects of penile squamous cell carcinoma (SCC) and the prevalence of HPV infection using high-risk HPV (hrHPV) and p16

resultsThe incidence of HPV was 53.2% for hrHPV and 22.32% for p16

conclusionsP16

Indexed as

AlphapapillomavirusCarcinoma, Squamous CellPapillomavirus InfectionsPenile Neoplasms5-MethylcytosineBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16DNA MethylationDNA, ViralEpigenesis, GeneticHumansMaleNeoplasm Recurrence, LocalPapillomaviridaePrognosis5-MethylcytosineBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16DNA, ViralGlobal DNA hydroxymethylationGlobal DNA methylationHigh-risk HPVHuman papillomavirusp16INK4aPenile cancer

Identifiers

PMID36284309
PMCPMC9597985
OpenAlexW4307201630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.